Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
A phase 1/2 trial of MDX2003 in non-Hodgkin lymphoma, waldenström macroglobulinaemia, diffuse large B-cell lymphoma and follicular lymphoma, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.
Overview
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma is a phase 1/2 interventional study registered as NCT07249905 by ModeX Therapeutics, An OPKO Health Company, with 180 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-01. Interventions recorded: MDX2003.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Shares Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Shares Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TrialSepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TrialStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Shares Waldenström macroglobulinaemia, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TrialA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.